US Stock Market Move | Weight loss drug sector stocks fall, Eli Lilly (LLY.US) plummets over 5%
Weight loss drug sector under pressure
On Thursday, the weight loss drug sector came under pressure. As of the time of writing, Eli Lilly (LLY.US) plummeted over 5%, with the company's weight loss drugs being added to the FDA review list, delaying the decision until April 10, 2026. Novo Nordisk A/S Sponsored ADR Class B (NVO.US) fell over 4%, while Pfizer Inc. (PFE.US) and Amgen (AMGN.US) dropped over 1%.
Related Articles
AV CONCEPT HOLD (00595) purchased 1 million shares for $380,800 on March 12th.
Power Construction Corporation of China, Ltd (POWERCHINA) signed a joint venture contract worth 13.962 billion yuan for a photovoltaic energy storage project EPC contract.
WHARF HOLDINGS (00004): Peter Tung to retire as independent non-executive director.
AV CONCEPT HOLD (00595) purchased 1 million shares for $380,800 on March 12th.
Power Construction Corporation of China, Ltd (POWERCHINA) signed a joint venture contract worth 13.962 billion yuan for a photovoltaic energy storage project EPC contract.
WHARF HOLDINGS (00004): Peter Tung to retire as independent non-executive director.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
